<DOC>
	<DOCNO>NCT00430170</DOCNO>
	<brief_summary>The purpose project explore interaction caffeine dipyridamole ischemia-reperfusion injury forearm .</brief_summary>
	<brief_title>Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury ?</brief_title>
	<detailed_description>Dipyridamole proven reduce target Annexin A5 responses ischemic exercise , indicate protection ischemia-reperfusion injury human ( pharmacological preconditioning ) . Dipyridamole increase endogenous adenosine level inhibition nucleoside transporter ( ENT-1 ) . Activation adenosine receptor protect ischemia-reperfusion injury . We hypothesize endogenous adenosine mediates protective effect dipyridamole ischemia-reperfusion injury . Therefore adenosine receptor antagonist caffeine reduce benefit dipyridamole forearm ischemia-reperfusion injury .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Male Age 1850yr . cardiovascular disease hypertension ( systole &gt; 140 mmHg , diastole &gt; 90 mmHg ) hypercholesterolemia ( random total cholesterol &gt; 6.5 mmol/l ) diabetes mellitus ( fast glucose &gt; 7.0 mmol/L random glucose &gt; 11.0 mmol/L ) asthma ( recurrent episode dyspnea wheezing , usage prescribe inhalation medication : i.e . corticosteroid B2agonists ) participation clinical trial last 60 day prior study . administration two dos Annexin A5 ( 0,1mg ; 450MBq ) last 5 year prior study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>ischemia-reperfusion injury</keyword>
	<keyword>adenosine</keyword>
	<keyword>dipyridamole</keyword>
	<keyword>caffeine</keyword>
</DOC>